MPM has collected three China drugs for its ‘best of both worlds’ strategy

Article

MPM has collected three China drugs for its ‘best of both worlds’ strategy

Source

MPM BioImpact, a leading biotech investor, is going all in on its strategy to take China-born drugs to the global stage. Over the past year, its portfolio company K2 Therapeutics has amassed three drug programs ...

Tweets, videos, filings, articles, and source pages tied to this read.

1
endpoints.newsendpoints.news